NCT02281591View on ClinicalTrials.gov

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Epilepsy
Interventions
DRUG

BIA 2-093

Tablets containing 900 mg

DRUG

S-licarbazepine

capsules containing 225 mg

DRUG

R-licarbazepine

capsules containing 225 mg

Trial Locations (1)

D-22525

Scope International Life Sciences AG,, Hamburg

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02281591 - Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine | Biotech Hunter | Biotech Hunter